ZNF660 and benign prostatic hyperplasia: To conduct a large‐scale evaluation of diagnostic and prognostic biomarker potential, we investigated ST6GALNAC3 and ZNF660 promoter methylation levels in 169 clinically localized PC samples (RP cohort 1) as well as in 16 AN, 12 BPH, 9 PIN, 15 MPC, and 7 CRPC tissue samples using qMSP (Table 1).